A cancer drug shrank tumors in 5 of 11 patients; 82% were estimated to be alive without worsening cancer at six months.
Xencor presented Phase 1 data for XmAb819, showing tumor shrinkage in 5 of 11 advanced ccRCC patients. The company plans FDA discussions for accelerated approval in 2027. XmAb819 demonstrated a 45% confirmed objective response rate in heavily pre-treated patients. Xencor will host a webcast to discuss the results and development plans.
How this was made
The 30-second read
Why it matters
The data provide a tangible efficacy signal for a first‑in‑class ENPP3‑targeted T‑cell engager, potentially accelerating regulatory discussions and influencing the company's cash‑runway outlook.
Market read
First‑time disclosure of promising Phase 1 data for a novel oncology candidate, likely to move Xencor's share price.
What to watch
Small patient numbers and exclusion of certain dose cohorts may limit the robustness of the response rate.
Background
Xencor presented its XmAb819 Phase 1 expansion results at the European Society for Medical Oncology (ESMO) meeting, outlining dose selection and response metrics in advanced clear cell renal cell carcinoma.
Ticker impact
Xencor disclosed Phase 1 expansion data for XmAb819 at ESMO, showing tumor shrinkage in 5 of 11 patients and a 45% confirmed response rate in a heavily pre‑treated ccRCC cohort.
likely upward pressure as market absorbs encouraging efficacy signals
Phase 1 results are the first public disclosure of efficacy; biotech stocks typically react strongly to early trial data.
Market effects
Adds momentum to the renal‑cell carcinoma immunotherapy space and may boost peer biotech valuations.
Primarily U.S. biotech market; limited immediate regional effect.
Highlights emerging bispecific antibody platforms, relevant to global oncology investors.
Counterpoint
Phase 1 data are early; efficacy may not translate to later‑stage trials, and safety signals could emerge.
Key entities
- companyXencor Inc.
Biopharma developing XmAb819 bispecific antibody.
- drugXmAb819
Bispecific antibody targeting ENPP3 in renal cell carcinoma.
